Diverse Emerging Therapies Featured at the 2025 Hope in Focus Conference in Minneapolis
The development of diverse treatment approaches for Leber congenital amaurosis (LCA) is necessary because no single modality will work for everyone affected....
The development of diverse treatment approaches for Leber congenital amaurosis (LCA) is necessary because no single modality will work for everyone affected....
The 2025 LCA Family Conference in Minneapolis, MN, offered four informational panel sessions, where the 135 attendees learned about living...
The second panel session of the 2025 LCA Family Conference, “Participating in a Clinical Trial,” examined clinical trial development and...
Through global data sharing and analysis, the nonprofit RARE-X (the research arm of Global Genes) is working to accelerate treatments for rare...
The community of people living with Leber congenital amaurosis caused by mutations in the RDH12 gene moved closer to realizing the shared...
We’ve heard a lot about therapies to correct mutations in specific genes causing blindness or low vision, and now research...
Innovative funding initiatives created by the Foundation Fighting Blindness are accelerating research advances to find treatments for Leber congenital amaurosis (LCA) and other rare inherited...
Working with preclinical data from multiple Leber congenital amaurosis (LCA) studies at the same time, Opus Genetics hopes to advance research into gene therapy...
Children living with visual impairment become more independent and empowered when parents set high expectations for their kids and challenge...
A proposed Congressional Act designed to help researchers launch clinical trials for emerging treatments gives hope for getting more treatments...